Inotiv (STU:BS50) LT-Debt-to-Total-Asset : 0.05 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Inotiv LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Inotiv's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.05.

Inotiv's long-term debt to total assets ratio declined from Mar. 2023 (0.46) to Mar. 2024 (0.05). It may suggest that Inotiv is progressively becoming less dependent on debt to grow their business.

Inotiv LT-Debt-to-Total-Asset Historical Data

The historical data trend for Inotiv's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv LT-Debt-to-Total-Asset Chart

Inotiv Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.33

0.36

0.50

0.37

0.47

Inotiv Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.46	0.47	0.47	0.49	0.05

Inotiv LT-Debt-to-Total-Asset Calculation

Inotiv's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (A: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2023 )	/	Total Assets (A: Sep. 2023 )
	=	374.246	/	802.569
	=	0.47

Inotiv's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	34.494	/	750.148
	=	0.05

Inotiv (STU:BS50) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Inotiv LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Inotiv's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv (STU:BS50) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

STIM FONR BNR ACRS PRPH VNRX MDXH BDSX BIOQ PSNL TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

NOTV:USA

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines